Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | UNG | P13051 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27346952 | 0.98 | HSD17B10 (0.57) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| Isophthalic Acid SCHEMBL28397170 | 0.82 | CA12 (0.65) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| Isophthalic Acid SCHEMBL209121 | 0.82 | CA12 (0.65) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| Isophthalic Acid SCHEMBL102783 | 0.82 | CA12 (0.65) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| SCHEMBL965605 | 0.82 | ATM (0.71) | HSD17B10HPGDCA1CA2KDM4E | |
| Isophthalic Acid SCHEMBL2512374 | 0.82 | CA12 (0.71) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| Isophthalic Acid SCHEMBL28462260 | 0.82 | CA12 (0.71) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| Isophthalic Acid SCHEMBL20500514 | 0.82 | CA12 (0.71) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| Isophthalic Acid SCHEMBL22462 | 0.82 | CA12 (0.71) | HSD17B10HPGDCYP1A2CYP2C9CA12 | |
| Isophthalic Acid SCHEMBL28756611 | 0.82 | CA12 (0.71) | HSD17B10HPGDCYP1A2CYP2C9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 775 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-04 | — | — | US | claimed |
| US-20230192657-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | GFB (ABC), LLC | 2023-06-22 | — | — | US | claimed |
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | VIVORYON THERAPEUTICS N.V. (DE) | 2023-04-20 | — | — | US | claimed |
| EP-4114838-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | Goldfinch Bio, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| CN-114585608-A | Heteroaromatic inhibitors of astacin protease | 维沃永治疗公众有限公司 | 2022-06-03 | — | — | CN | claimed |
| EP-3986868-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics N.V. (DE) | 2022-04-27 | — | — | EP | claimed |
| CN-109195947-B | Novel inhibitors of hypnotic proteins alpha and beta | 维沃里翁治疗股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | claimed |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | HISTOGEN, INC. | 2021-09-09 | — | — | US | claimed |
| EP-3814327-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | Histogen, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| EP-0378604-B1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES | ERBA CARLO SPA (IT) | 1994-03-02 | — | — | EP | claimed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | claimed |
| US-5157039-A | Lipoxygenase inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-10-20 | — | — | US | claimed |
| EP-0505413-A1 | BETA-LACTAM DERIVATIVES. | ERBA FARMITALIA (IT) | 1992-09-30 | — | — | EP | claimed |
| WO-1991009036-A1 | BETA-LACTAM DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-06-27 | — | — | WO | claimed |
| EP-0378604-A1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES. | ERBA CARLO SPA (IT) | 1990-07-25 | — | — | EP | claimed |
| WO-1989010926-A1 | 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-11-16 | — | — | WO | claimed |
| EP-0006784-B1 | DERIVATIVES OF L-CYSTEINE, THEIR USE AS MEDICAMENTS AND PROCESS FOR THEIR PREPARATION | SANOFI S.A. (FR) | 1982-05-19 | — | — | EP | claimed |
| US-3933800-A | O-SUBSTITUTED OXIMES, MICROBIOCIDES | GRUPPO LEPETIT S.P.A. (IT) | 1976-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122243-A1 | Heteroaromatic inhibitors of astacin proteinases | BMP1, DPEP1, MEP1A | HSD17B10 2223/4885HPGD 934/4885CYP1A2 1681/4885 |
| US-20210277014-A1 | (S)-3-(2-(4-(BENZYL)-3-OXOPIPERAZIN-1-YL)ACETAMIDO)-4-OXO-5-(2,3,5,6-TETRAFLUOROPHENOXY)PENTANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CASPASE INHIBITORS FOR TREATING CARDIOVASCULAR DISEASES | CASP1, CASP3, CASP6 | HSD17B10 1178/4885HPGD 3347/4885CYP1A2 742/4885 |
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | VIP, SGTA, NGLY1 | HSD17B10 4725/4885HPGD 4483/4885CYP1A2 4729/4885 |
| US-20230192657-A1 | 1,2,4-TRIAZOLINONE CB1 INHIBITORS | CNR1, GPR119, CNR2 | HSD17B10 722/4885HPGD 1230/4885CYP1A2 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.